AmerisourceBergen is driving innovative partnerships with global manufacturers, providers and pharmacies to improve product access and efficiency throughout the healthcare supply chain. As part of the largest global generics purchasing organization, the leading specialty pharmaceutical services provider and the partner with more community and health system pharmacy relationships than any other—we’re well positioned to help you capitalize on the dynamic changes in healthcare. From product and diagnostic commercialization, distribution to pharmacy, and provider and manufacturer solutions, we’re working with you every day to enhance patient care.
As part of AmerisourceBergen, Premier Source has access to diversified knowledge and expertise, unmatched reach and key strategic partnerships, which positions the company well to become a hub for personalized medicine, now and well into the future. Premier Source has a unique opportunity to help truly shape the delivery of precision healthcare for the patients that need it most.
Through Premier Source and AmerisourceBergen, you’ll have access to extensive knowledge and expertise across a wide range of essential competencies required to successfully bring much needed PMDxs to market. This expertise and knowledge includes everything from dispensing specialty medicines, devices and diagnostics through our considerable specialty pharmacy network to global sourcing and distribution. We have both the means and the expertise required to help you successfully bring your precision-medicine diagnostic to market, both domestically and abroad.
AmerisourceBergen gives Premier Source unmatched reach, leveraging the largest specialty physician network in the country. Through this specialty physician network, we have access to thousands of practices across a wide range of specialties including oncology, rheumatology, nephrology, urology and ophthalmology. Complementing this substantial specialty physician network is one of the largest specialty GPO networks, which offers significant collective-buying power and purchasing programs to manage the cost of care.
The close, hands-on, working relationship Premier Source’s team of experts has with our diagnostic clients enables us to truly understand the business challenges faced. There are a large number of AmerisourceBergen companies that we can call upon to address unique and difficult challenges as they arise.
Despite the cost-efficiency of more targeted treatment, barriers to access continue to exist, specifically for the companion diagnostics that play a critical role in ensuring the right therapeutic option is recommended to the right patient, at the right time. So how can diagnostic manufacturers overcome these barriers?
• Payers rely on diagnostics manufacturers to understand how a diagnostic aids in patient management with evidence that validates the predictive ability of the test and provides real-world learnings so they can adapt utilization management measures accordingly. Generating a combination of clinical and genomic/genetic data provides stronger rationale to payers for approval and use.
• Providers, from community practices to large health systems, need regular education about new diagnostics, clinical evidence to demonstrate the effectiveness of targeted therapies, and technology solutions that make it easier to integrate PM into practice workflow.
• And patients depend on reimbursement and financial assistance support programs to overcome challenges related to coverage and affordability.
AmerisourceBergen is committed to advancing the promise of personalized medicine. With knowledge of all relevant stakeholders, we have aggregated expertise from across our network and designed unique solutions to expand access and integrate personalized medicine so it can reach its full potential – improving outcomes for patients while driving efficiency across the healthcare continuum. Premier Source, as well as a number of other AmerisourceBergen companies, offer manufacturer solutions to drive product commercialization. Here are examples of those within our network that you can leverage to help successfully commercialize your precision-medicine diagnostic (PMDx).
Lash Group leverages 20 years of experience to strategically design, deliver and continuously improve patient access and adherence programs. From high-touch to high-tech, Lash Group’s patient support services ensure patients receive the best possible care, while strengthening product performance at every stage of its life cycle.
Through ION Solutions, Premier Source has extensive reach into the oncology community. ION Solutions is the largest oncology GPO in the nation, with 60 percent market share and GPO contracts with more than 20 manufacturers. ION Solutions has the knowledge and expertise required to successfully develop and deploy interoperable technology solutions that optimize clinical and business processes with the goal of increasing patient access, improving health outcomes and reducing the cost of care. ION Solutions gives providers tools like Nucleus Connect that manage workflow to make treating patients with targeted therapies seamless and more cost effective.
IntrinsiQ is the source of real-world oncology information and insight that hundreds of doctors, hospitals, and pharmaceutical companies trust. They collect real-world market intelligence that links genetics and clinical data through agreements with member practices through billing and clinical data from electronic medical records (EMRs), such as proprietary EMRs like Urochart and Meridian-Specialty.
Premier Source can also help bring precision-medicine diagnostics to market in Canada with the help of Innomar Strategies. Innomar Strategies knows how to negotiate the complex healthcare landscape in Canada. Their reach and expertise extends to every aspect of what is required for a product, device or diagnostic, regardless of where it is within its lifecycle – from licensure to handling and distribution to reimbursement and access to outcome assessment and evaluation, Innomar Strategies can do it all. Through its integrated service model, turnkey, tailored solutions are seamlessly developed that meet specific business needs.
Through Besse Medical, Premier Source can access the expertise in supporting product integrity, including cold chain management (including frozen). The company excels in the logistical management of biotech/specialty products (Rx and devices), vaccines and biologicals, brand name and generic injectables, diagnostic test kits and reagents, surgical anesthetics, oral, topical and ophthalmic pharmaceuticals and controlled substances, providing next-day delivery, Sunday for Monday shipments and their ability to produce pedigrees. The company also possesses comprehensive therapeutic experience in the following areas: rheumatology, gastroenterology, urology, neurology, dental, infectious disease, endocrinology and cardiology.
Through Xcenda, Premier Source can access the over 20 years of experience the company has as a consulting firm and payer agency with global capabilities. Xcenda helps manufacturers achieve two key goals — prove product value and maximize patient access. These are two very important elements required for the successful commercialization of any precision-medicine diagnostic. Xcenda implements evidence based strategies that utilize health economics and outcomes research to demonstrate the value of personalized medicine treatments, as well as their companion diagnostic, and provide actionable data to guide their utilization.
Pharmacies turn to AmerisourceBergen for powerful services and solutions that result in greater operational efficiency, cost control, growth opportunities and patient safety. That means industry-leading sourcing and distribution for products across the global healthcare supply chain. It also means solutions that help pharmacies improve their business performance, create opportunities to attract and retain patients and generate new revenue streams.
While personalized medicine faces significant hurdles to mainstream adoption, AmerisourceBergen has the knowledge, reach, and partnership to successfully commercialize these innovative technologies and their related biopharmaceutical treatments.